---
id: prosthetic-valve-endocarditis_079
category: clinical_syndromes
tags: [prosthetic-valve-endocarditis, PVE, coagulase-negative-staph, S-epidermidis, early-vs-late-PVE]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Prosthetic Valve Endocarditis (PVE)

**Q:** What are the microbiology, clinical features, diagnostic challenges, and treatment strategies for early vs. late prosthetic valve endocarditis (PVE)?

**A:**

**Definition:**
- **Prosthetic Valve Endocarditis (PVE):** Infection of prosthetic heart valve (mechanical or bioprosthetic)
- **10-30% of all IE cases**
- **Higher mortality** than native valve endocarditis (NVE): 20-40% vs 15-20%

---

**Classification:**

| **Type** | **Timing** | **Source** | **Microbiology** |
|----------|------------|------------|------------------|
| **Early PVE** | **<1 year post-op** | Healthcare-associated (perioperative contamination) | **CoNS** (40-50%), S. aureus (20%), GNRs, Candida |
| **Late PVE** | **>1 year post-op** | Community-acquired (similar to NVE) | Viridans strep, S. aureus, enterococcus, CoNS |

**Key Point:** **Early = CoNS #1** (nosocomial), **Late = viridans strep common** (community-acquired)

---

## MICROBIOLOGY

---

### **Early PVE (<1 Year Post-Op):**

**Most Common Pathogens:**

| **Organism** | **Frequency** | **Key Features** |
|--------------|---------------|------------------|
| **Coagulase-Negative Staphylococci (CoNS)** | **40-50%** | *S. epidermidis* most common<br>**Methicillin-resistant** (70-80%)<br>**Biofilm producer** |
| ***Staphylococcus aureus*** | **20%** | **MRSA common** (healthcare-associated)<br>High mortality (40-50%) |
| **Gram-Negative Bacilli** | **10-15%** | *Pseudomonas*, *E. coli*, *Klebsiella*, *Enterobacter* |
| **Fungi** | **5-10%** | *Candida* (albicans, parapsilosis, tropicalis)<br>**Almost always requires surgery** |
| **Enterococcus** | **5-10%** | *E. faecalis*, *E. faecium* |

**Risk Factors:**
- Prolonged ICU stay
- Prolonged operative time
- Perioperative bacteremia
- Reoperation within 1 year

---

### **Late PVE (>1 Year Post-Op):**

**Most Common Pathogens (Similar to NVE):**

| **Organism** | **Frequency** | **Key Features** |
|--------------|---------------|------------------|
| **Viridans Streptococci** | **25-30%** | *S. mitis*, *S. sanguinis*<br>Dental source common |
| ***Staphylococcus aureus*** | **20-25%** | **MSSA more common** (community-acquired)<br>High mortality |
| **Enterococcus** | **15-20%** | *E. faecalis* > *E. faecium* |
| **Coagulase-Negative Staphylococci (CoNS)** | **10-15%** | *S. epidermidis* |
| **HACEK** | **5%** | Slow-growing GNRs |

---

## CLINICAL FEATURES

**Presentation:**
- **More insidious than NVE** (especially CoNS)
- **Fever** (50-90% - may be low-grade)
- **New murmur** (20-50% - prosthesis may mask)
- **Heart failure** (20-40% - valve dysfunction, paravalvular leak)
- **Emboli** (20-40% - cerebral, splenic, renal)
- **Perivalvular complications common** (abscess, fistula, dehiscence)

**Key Point:** **PVE often presents with complications** (abscess, dehiscence) rather than isolated vegetation

---

## DIAGNOSIS

**Challenge:** **Echocardiography limited by prosthesis shadowing/artifacts**

---

### **Blood Cultures:**
- **≥3 sets** (before antibiotics)
- **Hold cultures ≥5 days** (CoNS may grow slowly)
- **Do NOT dismiss CoNS as contaminant** in setting of prosthetic valve

---

### **Echocardiography:**

**TTE:**
- **Sensitivity only 20-30% for PVE** (prosthesis shadows valve)
- **Limited for detecting paravalvular complications**

**TEE:**
- **Sensitivity 85-95% for PVE** (MANDATORY for suspected PVE)
- **Best for detecting:**
  - Paravalvular abscess
  - Valve dehiscence
  - Perivalvular leak

**Key Point:** **TEE MANDATORY** for all suspected PVE (TTE insufficient)

---

### **PET/CT or Cardiac CT (2023 Duke-ISCVID Update):**

**Indications:**
- **TEE negative** but high clinical suspicion
- **>3 months post-op** (to avoid false positives from post-surgical inflammation)

**Positive Finding:**
- **Abnormal FDG uptake** at prosthetic valve

**Efficacy:**
- **Increases PVE diagnostic sensitivity from ~70% to ~95%** (when added to Duke criteria)

**Key Point:** **PET/CT = game-changer for PVE diagnosis** (especially when TEE negative)

---

## TREATMENT

**Key Principles:**
- **Prolonged therapy** (≥6 weeks)
- **Combination therapy** often needed (β-lactam + gentamicin, rifampin)
- **Surgery often required** (50-70% of cases)

---

### **1. Coagulase-Negative Staphylococci (CoNS) - Most Common Early PVE**

**Empiric Regimen (Methicillin-Resistant CoNS - Assume MRSE):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q8-12h (target trough 15-20 μg/mL) | **≥6 weeks** |
| **PLUS** | | |
| **Rifampin** | 300 mg PO/IV q8h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

**Key Points:**
- **Rifampin** has excellent biofilm penetration (essential for CoNS PVE)
- **Start rifampin AFTER blood cultures clear** (avoid rifampin resistance if bacteremic)
- **Gentamicin x 2 weeks only** (then continue vancomycin + rifampin)

---

**If Methicillin-Susceptible CoNS (MSSE - Rare):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Nafcillin** OR **Oxacillin** | 2g IV q4h | **≥6 weeks** |
| **PLUS** | | |
| **Rifampin** | 300 mg PO/IV q8h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

---

### **2. *Staphylococcus aureus* PVE**

**MSSA PVE:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Nafcillin** OR **Oxacillin** | 2g IV q4h | **≥6 weeks** |
| **PLUS** | | |
| **Rifampin** | 300 mg PO/IV q8h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

---

**MRSA PVE:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) | **≥6 weeks** |
| **PLUS** | | |
| **Rifampin** | 300 mg PO/IV q8h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

**Alternative (Vancomycin Failure/Intolerance):**
- **Daptomycin** 10 mg/kg IV q24h (higher dose for endocarditis)

**Key Point:** **Rifampin essential for S. aureus PVE** (biofilm penetration)

---

### **3. Viridans Streptococcus PVE**

**Penicillin-Susceptible (MIC ≤0.12 μg/mL):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Penicillin G** | 24 million units/day IV continuous infusion OR divided q4h | **6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

**OR**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ceftriaxone** | 2g IV/IM q24h | **6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

**Key Point:** **PVE requires 6 weeks** (vs 4 weeks for NVE)

---

### **4. Enterococcus PVE**

**Ampicillin-Susceptible *E. faecalis*:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ampicillin** | 2g IV q4h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **6 weeks** |

**Key Point:** **Gentamicin x 6 weeks** (vs 2 weeks for NVE)

---

**Alternative (PCN Allergy):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **6 weeks** |

---

**High-Level Aminoglycoside Resistance (HLAR):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ampicillin** | 2g IV q4h | **8-12 weeks** |
| **PLUS** | | |
| **Ceftriaxone** | 2g IV q12h | **8-12 weeks** |

---

### **5. HACEK Organisms PVE**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ceftriaxone** | 2g IV/IM q24h | **6 weeks** |

---

### **6. Culture-Negative PVE**

**Empiric Regimen (Early PVE):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |
| **PLUS** | | |
| **Cefepime** | 2g IV q8h | **≥6 weeks** |
| **PLUS** | | |
| **Rifampin** | 300 mg PO/IV q8h | **≥6 weeks** |

**Covers:** MRSA, CoNS (with rifampin for biofilm), GNRs

---

**Empiric Regimen (Late PVE):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | **≥6 weeks** |
| **PLUS** | | |
| **Ceftriaxone** | 2g IV q24h | **≥6 weeks** |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | **2 weeks** |

**Covers:** Streptococcus, MRSA, enterococcus, HACEK

---

### **7. Fungal PVE (Candida, Aspergillus)**

**Treatment:**
- **Amphotericin B** 0.7-1 mg/kg IV q24h OR **Echinocandin** (caspofungin, micafungin)
- **Duration:** ≥6 weeks (if surgery) or **lifelong suppression** (if no surgery)

**Key Point:** **Surgery ALMOST ALWAYS required** for fungal PVE (medical therapy alone fails)

---

## SURGICAL INDICATIONS

**PVE Surgery More Common Than NVE (50-70% vs 40-50%):**

**Class I Indications (IDSA 2015 / ESC 2023):**

**1. Heart Failure:**
- **Severe prosthetic valve dysfunction** (obstruction or regurgitation)
- **Paravalvular leak** with heart failure

**2. Uncontrolled Infection:**
- **Perivalvular abscess**, fistula, or pseudoaneurysm
- **Persistent bacteremia** >5-7 days (despite appropriate antibiotics)
- **Fungal endocarditis** (almost always requires surgery)

**3. Prevention of Embolism:**
- **Recurrent emboli** despite antibiotics
- **Large mobile vegetation** (>10 mm)

**4. Prosthetic Valve-Specific:**
- **Valve dehiscence**
- **Early PVE** (especially if S. aureus, fungi, GNRs)

---

**Timing:**
- **Urgent surgery (<24-48h):** Severe heart failure, abscess with conduction block
- **Early surgery (within 1-2 weeks):** Uncontrolled infection, large vegetation

---

## OUTCOMES & PROGNOSIS

**Mortality:**
- **Early PVE:** 30-40%
- **Late PVE:** 20-30%
- **Fungal PVE:** 50-80%

**Predictors of Poor Outcome:**
- **S. aureus or fungal PVE**
- **Perivalvular abscess**
- **Heart failure**
- **CNS complications** (stroke, abscess)
- **Delayed surgery**

---

## ANTIBIOTIC PROPHYLAXIS FOR DENTAL PROCEDURES

**Indication:**
- **Prosthetic valve** (mechanical or bioprosthetic) = **HIGH-RISK**
- Prophylaxis for **dental procedures** with gingival manipulation

**Regimen:**
- **Amoxicillin** 2g PO x1 (30-60 min before procedure)
- **Clindamycin** 600 mg PO x1 (if PCN allergy)

**NOT Indicated For:**
- GI/GU procedures (unless active infection)

---

**Mnemonic: "CoNS Needs Rifampin" (Early PVE)**
- **C**oagulase-negative Staph = #1 early PVE
- **N**osocomial (healthcare-associated)
- **R**ifampin essential (biofilm penetration)

**Mnemonic: "PVE = Prolonged Vancomycin + Rifampin + Gentamicin"**
- **P**rolonged therapy (≥6 weeks)
- **V**ancomycin (empiric for CoNS, MRSA)
- **R**ifampin (biofilm penetration)
- **G**entamicin (synergy x 2 weeks)

**Mnemonic: "SAFER Surgery for PVE"**
- **S**evere heart failure (valve dysfunction)
- **A**bscess (perivalvular)
- **F**ungal endocarditis
- **E**arly PVE (especially S. aureus, GNRs, fungi)
- **R**ecurrent emboli or large vegetation

**Clinical Pearls:**
- **Early PVE (<1 year) = CoNS #1** (40-50%), **Late PVE (>1 year) = viridans strep** common
- **TEE MANDATORY** for all suspected PVE (TTE sensitivity only 20-30%)
- **PET/CT increases diagnostic sensitivity** from ~70% to ~95% (2023 Duke-ISCVID update)
- **Rifampin essential for CoNS/S. aureus PVE** (biofilm penetration) - start AFTER blood cultures clear
- **Triple therapy for staphylococcal PVE:** Vancomycin/nafcillin + rifampin + gentamicin (gent x 2 weeks)
- **Gentamicin duration:** 2 weeks (staphylococcal, streptococcal PVE) vs 6 weeks (enterococcal PVE)
- **Fungal PVE almost always requires surgery** (medical therapy alone fails)
- **Surgery more common for PVE than NVE** (50-70% vs 40-50%)
- **Early PVE surgery indications:** S. aureus, fungi, GNRs, persistent bacteremia
- **Do NOT dismiss CoNS as contaminant** in prosthetic valve patient (consider PVE)
- **PVE requires 6 weeks therapy** (vs 4 weeks for some NVE)
- **High mortality:** Early PVE 30-40%, fungal PVE 50-80%
- **Prophylaxis for prosthetic valve:** Amoxicillin 2g PO x1 before dental procedures

**Media:** None

**Sources:** [IDSA 2015 - Infective Endocarditis Guidelines], [ESC/EACTS 2023 - Endocarditis Guidelines], [JAMA 2023 - 2023 Duke-ISCVID Criteria], [PMC 2024 - PET/CT for PVE diagnosis], [AHA 2021 - Prosthetic Valve Endocarditis Management], [Circulation 2024 - CoNS biofilm infections]
